Biocon: anticancer biologics still largely unaffordable
This article was originally published in Scrip
Executive Summary
India's largest biotechnology firm, Biocon, has highlighted how, despite differential pricing, medicines for certain non-communicable diseases such as cancer are still beyond the reach of many patients in developing nations.